Evidence map›Paper›PMID 42417880›Full record

ArticleJournal of molecular histology2026

Correction: TAK-242 inhibits toll-like receptor-4 signaling and attenuates cancer-associated muscle atrophy via the p38-C/EBPβ pathway.

Yongfei You, Zhouzhou Su, Haozheng Wang, Shanshan Liu, Jiayi Wang, Feng Qiu, Zhiqun Jiang, Jianxin Wang, Yong Li, Guohua Zhang

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Yongfei YouDepartment of Medical Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi Province, China.
Zhouzhou SuQueen Mary School of Nanchang University, Nanchang, 330036, Jiangxi Province, China.
Haozheng WangQueen Mary School of Nanchang University, Nanchang, 330036, Jiangxi Province, China.
Shanshan LiuQueen Mary School of Nanchang University, Nanchang, 330036, Jiangxi Province, China.
Jiayi WangQueen Mary School of Nanchang University, Nanchang, 330036, Jiangxi Province, China.
Feng QiuDepartment of Medical Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi Province, China.
Zhiqun JiangDepartment of Neurosurgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi Province, China.
Jianxin WangDepartment of Urology, Taizhou First People's Hospital, Huangyan Hospital of Wenzhou Medical University, Taizhou, 318020, Zhejiang Province, China.
Yong LiDepartment of Medical Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi Province, China. liyong19_6@126.com.
Guohua ZhangDepartment of Medical Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi Province, China. zhanguohuazgh@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42417880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.